<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Onesource Specialty Pharma Ltd — News on 6ix</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd</link>
<description>Latest news and press releases for Onesource Specialty Pharma Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 13:33:17 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/onesource-specialty-pharma-ltd" rel="self" type="application/rss+xml" />
<item>
<title>Press Release Apr 29 2026</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-apr-29-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-apr-29-2026-5</guid>
<pubDate>Wed, 29 Apr 2026 13:33:17 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 29, 2026, titled "OneSource s Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection".</description>
</item>
<item>
<title>Press Release Apr 21 2026</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-apr-21-2026-12</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-apr-21-2026-12</guid>
<pubDate>Tue, 21 Apr 2026 12:23:32 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Orbicular s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner".</description>
</item>
<item>
<title>Press Release Feb 11 2026</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-feb-11-2026-45</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-feb-11-2026-45</guid>
<pubDate>Wed, 11 Feb 2026 13:22:53 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated February 11, 2026, "OneSource-Hikma partnership secures approval tocommercialise generic version of Ozempic® in Saudi Arabia".</description>
</item>
<item>
<title>Press Release Nov 11 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-nov-11-2025-28</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-nov-11-2025-28</guid>
<pubDate>Wed, 12 Nov 2025 03:14:59 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Financial results for the quarter ended September 30, 2025".</description>
</item>
<item>
<title>Inseego and National MSP OneSource Join Forces to Tackle the Growing 5G FWA Market Opportunity</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/inseego-and-national-msp-onesource-join-forces-to-tackle-the-growing-5g-fwa-market-opportunity</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/inseego-and-national-msp-onesource-join-forces-to-tackle-the-growing-5g-fwa-market-opportunity</guid>
<pubDate>Wed, 20 Aug 2025 20:05:00 GMT</pubDate>
<description>Wireless broadband leader’s fixed wireless access solutions at the core of OneSource’s new Janus solution for enterprise connectivitySAN DIEGO and HOUSTON, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Inseego Corp. (Nasdaq: INSG), a global leader in wireless broadband, including 5G mobile broadband, and 5G fixed wireless access (FWA) solutions, together with OneSource, a national connectivity service provider, today announced their partnership and the launch of Janus, OneSource’s new managed service. This</description>
</item>
<item>
<title>Press Release Aug 04 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-aug-04-2025-21</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-aug-04-2025-21</guid>
<pubDate>Tue, 05 Aug 2025 01:37:14 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated August 04, 2025, titled "Press release on financial results for the quarter ended June 30, 2025".</description>
</item>
<item>
<title>Press Release Jun 11 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jun-11-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jun-11-2025-10</guid>
<pubDate>Wed, 11 Jun 2025 12:32:24 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated Jun 11, 2025, titled "Press Release on subscription of equity shares of Xbrane Biopharma AB, Sweden".</description>
</item>
<item>
<title>Press Release Jun 10 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jun-10-2025-9</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jun-10-2025-9</guid>
<pubDate>Tue, 10 Jun 2025 12:41:24 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated Jun 10, 2025, titled "Press Release on US-FDA Compliance status for OneSource".</description>
</item>
<item>
<title>Press Release May 05 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-may-05-2025-14</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-may-05-2025-14</guid>
<pubDate>Tue, 06 May 2025 00:30:01 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 05, 2025, titled "Press release ".</description>
</item>
<item>
<title>Press Release Apr 10 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-apr-10-2025-8</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-apr-10-2025-8</guid>
<pubDate>Thu, 10 Apr 2025 16:07:31 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated April 10, 2025, titled "Press Release w.r.t Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, for OneSource flagship Unit 2 facility".</description>
</item>
<item>
<title>Press Release Feb 28 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-feb-28-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-feb-28-2025-12</guid>
<pubDate>Fri, 28 Feb 2025 23:57:29 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated February 28, 2025, titled "Intimation of press release of the Company w.r.t strengthening its Board by the appointment of three new independent directors dated February 28,2025.".</description>
</item>
<item>
<title>Press Release Jan 29 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jan-29-2025-30</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jan-29-2025-30</guid>
<pubDate>Wed, 29 Jan 2025 12:43:51 GMT</pubDate>
<description>Earnings Presentation for the quarter ended December 31,2024</description>
</item>
<item>
<title>Press Release Jan 28 2025</title>
<link>https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jan-28-2025-33</link>
<guid isPermaLink="true">https://6ix.com/company/onesource-specialty-pharma-ltd/news/press-release-jan-28-2025-33</guid>
<pubDate>Wed, 29 Jan 2025 02:40:16 GMT</pubDate>
<description>Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated January 28, 2025, titled "OneSource receives EIR with 'Voluntary Action Indicated' classification from USFDA for its BLD Facility".</description>
</item>
</channel>
</rss>